A5070262210- Adenosine and Purinergic Signaling
- Biochemical and Molecular Research
- HIV/AIDS drug development and treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Ubiquitin and proteasome pathways
- Cancer Immunotherapy and Biomarkers
- DNA Repair Mechanisms
- Pancreatic and Hepatic Oncology Research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Calcium signaling and nucleotide metabolism
- Click Chemistry and Applications
- DNA and Nucleic Acid Chemistry
- Cytomegalovirus and herpesvirus research
- Cancer-related Molecular Pathways
- Pneumocystis jirovecii pneumonia detection and treatment
- Peptidase Inhibition and Analysis
- Synthesis and Biological Evaluation
- Immunotherapy and Immune Responses
- Multiple Myeloma Research and Treatments
- Antibiotic Resistance in Bacteria
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
Centre de Recherche en Cancérologie de Lyon
2016-2025
Centre National de la Recherche Scientifique
2016-2025
Université Claude Bernard Lyon 1
2016-2025
Inserm
2016-2025
Centre Léon Bérard
2016-2025
Institut des Sciences Analytiques
2023
Laboratoire de Chimie
2015-2023
Hospices Civils de Lyon
2013-2022
Institut des Sciences Biologiques
2021
University of Bergen
2019
In spite of impressive response rates in multiple cancer types, immune checkpoint inhibitors (ICIs) are active only a minority patients. Alternative strategies currently aim to combine immunotherapies with conventional agents such as cytotoxic chemotherapies. Here, we performed study PD-1 or PDL-1 blockade combination reference chemotherapies four fully immunocompetent mouse models cancer. We analyzed both the vivo antitumor response, and tumor infiltrate days after first treatment. growth...
The benefit of cancer chemotherapy based on alkylating agents is limited because the action DNA repair enzymes, which mitigate damage induced by these agents. interaction between proteins ERCC1 and XPF involves two major components nucleotide excision pathway. Here, novel inhibitors this were identified virtual screening available structures with use National Cancer Institute diversity set a panel DrugBank small molecules. Subsequently, experimental validation in silico was undertaken. Top...
mRNA based infectious disease vaccines have opened the venue for development of novel nucleic acids-based therapeutics. For all therapeutics dedicated delivery systems are required, where different functionalities and targeting abilities need to be optimized respective applications. One option advanced formulations with tailored properties lipid-polymer hybrid nanoparticles complex nanostructure, which allow combine features several already well described acid systems. Here, we explored...
Background Nucleotide excision repair (NER) removes many types of DNA lesions including those induced by UV radiation and platinum-based therapy. Resistance to therapy correlates with high expression ERCC1, a major element the NER machinery. The interaction between ERCC1 XPA is essential for successful function. Therefore, one way regulate inhibiting activity XPA. Methodology/Principal Findings Here we continued our earlier efforts aimed at identification characterization novel inhibitors...
Summary. The cytotoxic activity of cytarabine (ara‐C) in leukaemic blasts depends on activating enzymes such as deoxycytidine kinase (dCK) and inactivating the 5′‐nucleotidases. We have analysed dCK ‘high‐Km’ 5′‐nucleotidase (cN‐II) mRNA expression by quantitative real‐time polymerase chain reaction at diagnosis from 115 acute myeloid leukaemia (AML) patients treated with ara‐C. prognostic value these parameters well that cN‐II/dCK ratio was determined. In univariate analyses: (1) low levels...
The rise of antimicrobial resistance (AMR) worldwide and the increasing spread multi-drug-resistant organisms expressing metallo-β-lactamases (MBL) require development efficient clinically available MBL inhibitors. At present, no such inhibitor is available, research urgently needed to advance this field. We report herein development, synthesis, biological evaluation chemical compounds based on selective zinc chelator tris-picolylamine (TPA) that can restore bactericidal activity Meropenem...
Abstract Antibodies targeting PD-1 and PD-L1 have produced durable responses in a subset of patients with cancer. However, majority these will ultimately relapse due to acquired resistance. To explore the underlying mechanisms this secondary resistance, we developed five syngeneic murine tumor variants resistance anti–PD-1 and/or antibodies vivo. Resistant vivo models were obtained by serial treatment/reimplantation cycles MC38 colorectal, MB49 MBT2 bladder, RENCA kidney TyrNras melanoma...
Abstract Resistance to cytotoxic nucleoside analogues is a major problem in cancer treatment. The cellular mechanisms involved this phenomenon have been studied for several years, and some factors identified. However, resistance seems be multifactorial more studies are needed gain better insight into domain. For purpose, we developed gemcitabine-resistant cell line (MCF7 1K) from the human mammary adenocarcinoma MCF7 strain by prolonged exposure gemcitabine vitro. 1K cells highly resistant...
Abstract Resistance to cytotoxic nucleoside analogues is a major problem in cancer treatment. The cellular mechanisms involved this phenomenon have been studied for several years, and some factors identified. Various strategies overcome resistance suggested, but none has yet shown efficacy vivo. We developed gemcitabine-resistant cell line (L1210 10K) from the murine leukemic L1210 strain wt) by continuous exposure increasing concentrations of gemcitabine. 10K highly resistant gemcitabine...